21.06.2011 • News

Trial Set For Teva-Mylan Copaxone Lawsuit

A U.S. court on Friday denied a motion by Teva Pharmaceutical Industries for summary judgment in the Copaxone patent infringement lawsuit it has brought against Mylan Inc.    

Teva is suing generic drugmaker Mylan for infringement of patents covering Teva's top-selling Copaxone multiple sclerosis drug.      

Mylan said on Friday that the U.S. District Court for the Southern District of New York has denied Teva's motion for summary judgment.      

In addition, the court set a start date of July 11 for the trial regarding Mylan's inequitable conduct affirmative defense.      

The remaining issues will be tried beginning Sept. 7, Mylan said in a statement.      

The potential for a generic Copaxone is a major issue weighing on shares of Israel-based Teva.

 

 

 

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Top-Feature

most read